title: Critical and controlled tests of activity of moxidectin (CL 301,423) against natural infections of internal parasites of equids.
abstract: The activity of moxidectin was evaluated in 1988 and 1989 against natural infections of internal parasites in 20 critical tests (n = 20 equids) and three controlled tests (n = 20 equids). Two formulations, injectable administered intramuscularly (i.m.) or intraorally (i.o.) and gel i.o., were given at dose rates of 0.2, 0.3 or 0.4 mg kg-1 body weight. For the critical tests (all three dose rates evaluated), removals of second instar Gasterophilus intestinalis were 93-100%, except (89%) for the injectable formulation (i.m.) at 0.2 mg kg-1. Removals of third instar G. intestinalis were 88-100% for the injectable formulation given i.m. or i.o. and 93-100% for the gel formulation, except (53%) for one batch (0.4 mg kg-1). Activity was 100% for third instar Gasterophilus nasalis, Parascaris equorum, Strongylus vulgaris and Strongylus edentatus. For Oxyuris equi, removals were 91-100%, except (27%) for one batch of the injectable formulation given i.o. at 0.3 mg kg-1. There was apparent activity against migrating S. vulgaris and S. edentatus at various dose rates and routes of administration for both formulations. At necropsy, there were local reactions observed at the injection site of three equids. In the controlled tests, dose rates were 0.2 or 0.4 mg kg-1. Removal of third instar G. intestinalis was highest for the injectable formulation given i.m. All formulations and dose rates were highly effective against S. vulgaris and S. edentatus, but variable and incomplete against O. equi. Removal was excellent on Habronema muscae and on migrating S. vulgaris and S. edentatus, although incomplete on S. vulgaris. Gasterophilus nasalis third instars and P. equorum were present in low numbers in some non-treated equids, but none were recovered from treated equids. Toxicosis was not evident.
authors.affiliation: Department of Veterinary Science, Gluck Equine Research Center, University of Kentucky, Lexington 40546-0099.
authors.forename: E T
authors.initials: ET
authors.lastname: Lyons
authors.forename: S C
authors.initials: SC
authors.lastname: Tolliver
authors.forename: J H
authors.initials: JH
authors.lastname: Drudge
authors.forename: D E
authors.initials: DE
authors.lastname: Granstrom
authors.forename: S S
authors.initials: SS
authors.lastname: Collins
authors.forename: S
authors.initials: S
authors.lastname: Stamper
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007273:Injections, Intramuscular / Q000662:veterinary; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy / Q000662:veterinary*; D018942:Macrolides; D008297:Male; D010272:Parasitic Diseases / Q000188:drug therapy; D010273:Parasitic Diseases, Animal
chemical_list: D000871:Anthelmintics; D000900:Anti-Bacterial Agents; D005782:Gels; D018942:Macrolides; C027837:moxidectin